Skip NavigationSkip to Content
Return Return to Search Results

Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA

  1. Author:
    Newton, D. L.
    Rybak, S. M.

  2. Author Address

    NCI, Frederick Canc Res & Dev Ctr, SAIC Frederick, Frederick, MD 21702 USA NCI, Frederick Canc Res & Dev Ctr, SAIC Frederick, Frederick, MD 21702 USA NCI, Frederick Canc Res & Dev Ctr, Dev Therapeut Program, Div Canc Treatment & Diag, Frederick, MD 21702 USA Rybak SM NCI, Frederick Canc Res & Dev Ctr, SAIC Frederick, Frederick, MD 21702 USA
    1. Year: 2001
  2. Journal: Expert Opinion on Biological Therapy
    1. 1
    2. 6
    3. Pages: 995-1003
  4. Type of Article: Review
  1. Abstract:

    The approval of antibodies for cancer treatment has provoked increased interest in the development of new and improved antibody-mediated therapies. This emerging approach centres on targeting CD22 on human B-cells with a monoclonal antibody (mAb). Anti-CD22 antibodies conjugated to a cytotoxic RNAse elicits potent and specific killing of the lymphoma cells in vitro and in human lymphoma models in severe combined immune deficiency (SCID) mice. RNA damage caused by RNAses could be an important alternative to standard DNA damaging chemotherapeutics. Moreover, targeted RNAses may overcome problems of toxicity and immunogenicity associated with plant- or bacterial toxin-containing immunotoxins.

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel